PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function.


Journal

Nature chemical biology
ISSN: 1552-4469
Titre abrégé: Nat Chem Biol
Pays: United States
ID NLM: 101231976

Informations de publication

Date de publication:
08 2020
Historique:
received: 22 08 2019
accepted: 22 04 2020
pubmed: 27 5 2020
medline: 24 11 2020
entrez: 27 5 2020
Statut: ppublish

Résumé

The orphan nuclear receptor Nurr1 is critical for the development, maintenance and protection of midbrain dopaminergic (mDA) neurons. Here we show that prostaglandin E1 (PGE1) and its dehydrated metabolite, PGA1, directly interact with the ligand-binding domain (LBD) of Nurr1 and stimulate its transcriptional function. We also report the crystallographic structure of Nurr1-LBD bound to PGA1 at 2.05 Å resolution. PGA1 couples covalently to Nurr1-LBD by forming a Michael adduct with Cys566, and induces notable conformational changes, including a 21° shift of the activation function-2 helix (H12) away from the protein core. Furthermore, PGE1/PGA1 exhibit neuroprotective effects in a Nurr1-dependent manner, prominently enhance expression of Nurr1 target genes in mDA neurons and improve motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse models of Parkinson's disease. Based on these results, we propose that PGE1/PGA1 represent native ligands of Nurr1 and can exert neuroprotective effects on mDA neurons, via activation of Nurr1's transcriptional function.

Identifiants

pubmed: 32451509
doi: 10.1038/s41589-020-0553-6
pii: 10.1038/s41589-020-0553-6
pmc: PMC7405943
mid: NIHMS1598692
doi:

Substances chimiques

Ligands 0
NR4A2 protein, human 0
Neuroprotective Agents 0
Nuclear Receptor Subfamily 4, Group A, Member 2 0
Prostaglandins A 0
Alprostadil F5TD010360
Dopamine VTD58H1Z2X
prostaglandin A1 VYR271N44P

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

876-886

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS070577
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS084869
Pays : United States
Organisme : NIH HHS
ID : R24 OD024622
Pays : United States

Références

Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835–839 (1995).
pubmed: 8521507 pmcid: 6159888 doi: 10.1016/0092-8674(95)90199-X
Evans, R. M. & Mangelsdorf, D. J. Nuclear receptors, RXR, and the big bang. Cell 157, 255–266 (2014).
pubmed: 24679540 pmcid: 4029515 doi: 10.1016/j.cell.2014.03.012
Kliewer, S. A., Lehmann, J. M. & Willson, T. M. Orphan nuclear receptors: shifting endocrinology into reverse. Science 284, 757–760 (1999).
pubmed: 10221899 doi: 10.1126/science.284.5415.757
Kurakula, K., Koenis, D. S., van Tiel, C. M. & de Vries, C. J. NR4A nuclear receptors are orphans but not lonesome. Biochim Biophys. Acta 1843, 2543–2555 (2014).
pubmed: 24975497 doi: 10.1016/j.bbamcr.2014.06.010
Pearen, M. A. & Muscat, G. E. Minireview: nuclear hormone receptor 4A signaling: implications for metabolic disease. Mol. Endocrinol. 24, 1891–1903 (2010).
pubmed: 20392876 pmcid: 5417389 doi: 10.1210/me.2010-0015
Zetterstrom, R. H. et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248–250 (1997).
pubmed: 9092472 doi: 10.1126/science.276.5310.248
Kadkhodaei, B. et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 29, 15923–15932 (2009).
pubmed: 20016108 pmcid: 6666174 doi: 10.1523/JNEUROSCI.3910-09.2009
Saijo, K. et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137, 47–59 (2009).
pubmed: 19345186 pmcid: 2754279 doi: 10.1016/j.cell.2009.01.038
Chu, Y. et al. Nurr1 in Parkinson’s disease and related disorders. J. Comp. Neurol. 494, 495–514 (2006).
pubmed: 16320253 pmcid: 2564615 doi: 10.1002/cne.20828
Moran, L. B. et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed Parkinsonian nigra. Acta Neuropathol. 113, 253–263 (2007).
pubmed: 17203291 doi: 10.1007/s00401-006-0181-6
Decressac, M., Volakakis, N., Bjorklund, A. & Perlmann, T. NURR1 in Parkinson disease–from pathogenesis to therapeutic potential. Nat. Rev. Neurol. 9, 629–636 (2013).
pubmed: 24126627 doi: 10.1038/nrneurol.2013.209
Kim, C. H., Leblanc, P. & Kim, K. S. 4-amino-7-chloroquinoline derivatives for treating Parkinson’s disease: implications for drug discovery. Expert Opin. Drug Discov. 11, 337–341 (2016).
pubmed: 26924734 pmcid: 4810450 doi: 10.1517/17460441.2016.1154529
Kim, K. S. Toward neuroprotective treatments of Parkinson’s disease. Proc. Natl Acad. Sci. USA 114, 3795–3797 (2017).
pubmed: 28360200 doi: 10.1073/pnas.1703362114 pmcid: 5393211
Wang, Z. et al. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423, 555–560 (2003).
pubmed: 12774125 doi: 10.1038/nature01645
Kagaya, S. et al. Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily. Biol. Pharm. Bull. 28, 1603–1607 (2005).
pubmed: 16141523 doi: 10.1248/bpb.28.1603
Lakshmi, S. P., Reddy, A. T., Banno, A. & Reddy, R. C. Molecular, chemical, and structural characterization of prostaglandin A2 as a novel agonist for Nur77. Biochem. J. 476, 2757–2767 (2019).
pubmed: 31492735 doi: 10.1042/BCJ20190253
Vinayavekhin, N. & Saghatelian, A. Discovery of a protein-metabolite interaction between unsaturated fatty acids and the nuclear receptor Nur77 using a metabolomics approach. J. Am. Chem. Soc. 133, 17168–17171 (2011).
pubmed: 21973308 pmcid: 4569094 doi: 10.1021/ja208199h
de Vera, I. M. et al. Identification of a binding site for unsaturated fatty acids in the orphan nuclear receptor Nurr1. ACS Chem. Biol. 11, 1795–1799 (2016).
pubmed: 27128111 pmcid: 4946999 doi: 10.1021/acschembio.6b00037
de Vera, I. M. S. et al. Defining a canonical ligand-binding pocket in the orphan nuclear receptor Nurr1. Structure 27, 66–77 e65 (2019).
pubmed: 30416039 doi: 10.1016/j.str.2018.10.002
Chintharlapalli, S. et al. Activation of Nur77 by selected 1,1-bis(3′-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J. Biol. Chem. 280, 24903–24914 (2005).
pubmed: 15871945 doi: 10.1074/jbc.M500107200
Zhan, Y. et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat. Chem. Biol. 4, 548–556 (2008).
pubmed: 18690216 doi: 10.1038/nchembio.106
Kim, C. H. et al. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 112, 8756–8761 (2015).
pubmed: 26124091 doi: 10.1073/pnas.1509742112 pmcid: 4507186
Andersen, N. H. Dehydration of prostaglandins: study by spectroscopic method. J. Lipid Res. 10, 320–325 (1969).
pubmed: 5785003 doi: 10.1016/S0022-2275(20)43090-1
Itoh, T. et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct. Mol. Biol. 15, 924–931 (2008).
pubmed: 19172745 pmcid: 2939985 doi: 10.1038/nsmb.1474
Codina, A. et al. Identification of a novel co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting. J. Biol. Chem. 279, 53338–53345 (2004).
pubmed: 15456745 doi: 10.1074/jbc.M409096200
Aarnisalo, P., Kim, C. H., Lee, J. W. & Perlmann, T. Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1. J. Biol. Chem. 277, 35118–35123 (2002).
pubmed: 12130634 doi: 10.1074/jbc.M201707200
Zhan, Y. Y. et al. The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat. Chem. Biol. 8, 897–904 (2012).
pubmed: 22983157 doi: 10.1038/nchembio.1069
Li, L. et al. Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. Nat. Chem. Biol. 11, 339–346 (2015).
pubmed: 25822914 doi: 10.1038/nchembio.1788
Wang, W. J. et al. Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway. Nat. Chem. Biol. 10, 133–140 (2014).
pubmed: 24316735 doi: 10.1038/nchembio.1406
Wang, W. J. et al. Induction of autophagic death in cancer cells by agonizing TR3 and attenuating Akt2 activity. Chem. Biol. 22, 1040–1051 (2015).
pubmed: 26235054 doi: 10.1016/j.chembiol.2015.06.023
Furuyashiki, T. & Narumiya, S. Stress responses: the contribution of prostaglandin E(2) and its receptors. Nat. Rev. Endocrinol. 7, 163–175 (2011).
pubmed: 21116297 doi: 10.1038/nrendo.2010.194
Carrasco, E., Casper, D. & Werner, P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J. Neurosci. Res. 85, 3109–3117 (2007).
pubmed: 17868147 doi: 10.1002/jnr.21425
Parga, J. A. et al. Prostaglandin EP2 receptors mediate mesenchymal stromal cell-neuroprotective effects on dopaminergic neurons. Mol. Neurobiol. 55, 4763–4776 (2018).
pubmed: 28717970 doi: 10.1007/s12035-017-0681-5
Xu, H. et al. The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif. Biochemistry 48, 12159–12168 (2009).
pubmed: 19916559 doi: 10.1021/bi901188s
Becker, W., Bhattiprolu, K. C., Gubensak, N. & Zangger, K. Investigating protein-ligand interactions by solution nuclear magnetic resonance spectroscopy. Chem. Phys. Chem. 19, 895–906 (2018).
pubmed: 29314603 doi: 10.1002/cphc.201701253
Choi, H. K., Won, L., Roback, J. D., Wainer, B. H. & Heller, A. Specific modulation of dopamine expression in neuronal hybrid cells by primary cells from different brain regions. Proc. Natl Acad. Sci. USA 89, 8943–8947 (1992).
pubmed: 1357658 doi: 10.1073/pnas.89.19.8943 pmcid: 50040
Gao, L., Zhou, W., Symmes, B. & Freed, C. R. Re-cloning the N27 dopamine cell line to improve a cell culture model of Parkinson’s disease. PLoS ONE 11, e0160847 (2016).
pubmed: 27512998 pmcid: 4981411 doi: 10.1371/journal.pone.0160847
af Forselles, K. J. et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist. Br. J. Pharmacol. 164, 1847–1856 (2011).
pubmed: 21595651 pmcid: 3246710 doi: 10.1111/j.1476-5381.2011.01495.x
Bergstroem, S. & Samuelsson, B. Prostaglandins. Annu. Rev. Biochem. 34, 101–108 (1965).
pubmed: 14321164 doi: 10.1146/annurev.bi.34.070165.000533
Higdon, A., Diers, A. R., Oh, J. Y., Landar, A. & Darley-Usmar, V. M. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem. J. 442, 453–464 (2012).
pubmed: 22364280 doi: 10.1042/BJ20111752
Qin, Z. H. et al. Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum. J. Pharmacol. Exp. Ther. 297, 78–87 (2001).
pubmed: 11259530
Wang, X. et al. Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells. J. Neurochem. 83, 1094–1102 (2002).
pubmed: 12437580 doi: 10.1046/j.1471-4159.2002.01224.x
Zhang, H. L. et al. Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia. Brain Res. 1039, 203–206 (2005).
pubmed: 15781063 doi: 10.1016/j.brainres.2005.01.046
Bruning, J. M. et al. Covalent modification and regulation of the nuclear receptor nurr1 by a dopamine metabolite. Cell Chem. Biol. 26, 674–685 e676 (2019).
pubmed: 30853418 pmcid: 7185887 doi: 10.1016/j.chembiol.2019.02.002
de Urquiza, A. M. et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140–2144 (2000).
pubmed: 11118147 doi: 10.1126/science.290.5499.2140
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. & Mangelsdorf, D. J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383, 728–731 (1996).
pubmed: 8878485 doi: 10.1038/383728a0
Powell, W. S. 15-Deoxy-delta12,14-PGJ2: endogenous PPARgamma ligand or minor eicosanoid degradation product? J. Clin. Invest. 112, 828–830 (2003).
pubmed: 12975467 pmcid: 193674 doi: 10.1172/JCI19796
Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D. 67, 271–281 (2011).
pubmed: 21460445 doi: 10.1107/S0907444910048675 pmcid: 3069742
Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D. 62, 72–82 (2006).
pubmed: 16369096 doi: 10.1107/S0907444905036693
Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D. 67, 235–242 (2011).
pubmed: 21460441 doi: 10.1107/S0907444910045749 pmcid: 3069738
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840 pmcid: 2483472 doi: 10.1107/S0021889807021206
Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D. 67, 355–367 (2011).
pubmed: 21460454 doi: 10.1107/S0907444911001314 pmcid: 3069751
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. 60, 2126–2132 (2004).
pubmed: 15572765 doi: 10.1107/S0907444904019158
Pettersen, E. F. et al. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
pubmed: 15264254
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. 66, 213–221 (2010).
pubmed: 20124702 doi: 10.1107/S0907444909052925 pmcid: 2815670
Waudby, C. A., Ramos, A., Cabrita, L. D. & Christodoulou, J. Two-dimensional NMR lineshape analysis. Sci. Rep. 6, 24826 (2016).
pubmed: 27109776 pmcid: 4843008 doi: 10.1038/srep24826
Leblanc, P. et al. Production of Nurr-1 specific polyclonal antibodies free of cross-reactivity against its close homologs, Nor1 and Nur77. J. Vis. Exp. 102, e52963 (2015).
Kim, W. et al. miR-126 contributes to Parkinson’s disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol. Aging 35, 1712–1721 (2014).
pubmed: 24559646 pmcid: 3991567 doi: 10.1016/j.neurobiolaging.2014.01.021
Chen, S. H., Oyarzabal, E. A. & Hong, J. S. Preparation of rodent primary cultures for neuron-glia, mixed glia, enriched microglia, and reconstituted cultures with microglia. Methods Mol. Biol. 1041, 231–240 (2013).
pubmed: 23813383 pmcid: 4788376 doi: 10.1007/978-1-62703-520-0_21

Auteurs

Sreekanth Rajan (S)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.

Yongwoo Jang (Y)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Department of Biomedical Engineering, Hanyang University, Seoul, Korea.

Chun-Hyung Kim (CH)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Paean Biotechnology, Daejeon, Korea.

Woori Kim (W)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.

Hui Ting Toh (HT)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Nanyang Institute of Technology in Health and Medicine, Interdisciplinary Graduate School, Nanyang Technological University, Singapore, Singapore.

Jeha Jeon (J)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.

Bin Song (B)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.

Aida Serra (A)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.

Julien Lescar (J)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
NTU Institute of Structural Biology, Nanyang Technological University, Singapore, Singapore.

Jun Yeob Yoo (JY)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.

Serap Beldar (S)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.

Hong Ye (H)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.

Congbao Kang (C)

Experimental Drug Development Centre, Agency for Science, Technology and Research, Nanos, Singapore, Singapore.

Xue-Wei Liu (XW)

Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, Singapore, Singapore.

Melissa Feitosa (M)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.

Yeahan Kim (Y)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.

Dabin Hwang (D)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.

Geraldine Goh (G)

National Neuroscience Institute, Singapore, Singapore.

Kah-Leong Lim (KL)

National Neuroscience Institute, Singapore, Singapore.
Lee Kong Chian School of Medicine, Singapore, Singapore.

Hye Min Park (HM)

Department of Bioscience and Biotechnology, Konkuk University, Gwangjin-gu, Seoul, Republic of Korea.

Choong Hwan Lee (CH)

Department of Bioscience and Biotechnology, Konkuk University, Gwangjin-gu, Seoul, Republic of Korea.

Sungwhan F Oh (SF)

Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Gregory A Petsko (GA)

Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Ho Sup Yoon (HS)

School of Biological Sciences, Nanyang Technological University, Singapore, Singapore. hsyoon@ntu.edu.sg.
NTU Institute of Structural Biology, Nanyang Technological University, Singapore, Singapore. hsyoon@ntu.edu.sg.

Kwang-Soo Kim (KS)

Molecular Neurobiology Laboratory, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA. kskim@mclean.harvard.edu.
Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital, Harvard Medical School, Belmont, MA, USA. kskim@mclean.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH